Phaarmasia Intrinsic Value
Phaarmasia (PHRMASI) median intrinsic value is ₹164.74 from 8 valuation models (range ₹26–₹298), vs current price ₹99.23 — +66.0% upside (Trading Below Calculated Value), margin of safety 39.8%. Analyse PHRMASI promoter holding to track promoter, FII and institutional holdings.
PHRMASI Valuation Methods Summary — DCF, Graham Number & P/E
Phaarmasia intrinsic value across 8 models vs current price ₹99.23 — upside/downside and value range per method. For current market price and key ratios, visit Phaarmasia screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹297.69 | ₹238.15 - ₹357.23 | +200.0% | EPS: ₹25.74, Sector P/E: 22x |
| Book Value Method | asset | ₹25.71 | ₹23.14 - ₹28.28 | -74.1% | Book Value/Share: ₹12.86, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹134.29 | ₹120.86 - ₹147.72 | +35.3% | Revenue/Share: ₹67.14, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹39.69 | ₹35.72 - ₹43.66 | -60.0% | EBITDA: ₹2.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹164.74 | ₹148.27 - ₹181.21 | +66.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹297.69 | ₹267.92 - ₹327.46 | +200.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹198.46 | ₹178.61 - ₹218.31 | +100.0% | ROE: 200.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹29.77 | ₹26.79 - ₹32.75 | -70.0% | EPS: ₹25.74, BVPS: ₹12.86 |
PHRMASI Intrinsic Value vs Market Price — All Valuation Models
Phaarmasia fair value range ₹26–₹298 vs current market price ₹99.23 across 8 valuation models. Read PHRMASI dividend payout details for the complete payout history and dividend yield track record.
PHRMASI Intrinsic Value Analysis — Undervalued or Overvalued?
Phaarmasia median intrinsic value ₹164.74, current price ₹99.23 — Trading Below Calculated Value by 66.0%, margin of safety 39.8%.
What is the intrinsic value of PHRMASI?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Phaarmasia (PHRMASI) is ₹164.74 (median value). With the current market price of ₹99.23, this represents a +66.0% variance from our estimated fair value.
The valuation range spans from ₹25.71 to ₹297.69, indicating ₹25.71 - ₹297.69.
Is PHRMASI undervalued or overvalued?
Based on our multi-method analysis, Phaarmasia (PHRMASI) appears to be trading below calculated value by approximately 66.0%.
PHRMASI Financial Health — Key Ratios vs Industry Benchmarks
Phaarmasia financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 200.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.14x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
PHRMASI Cash Flow Quality — Operating & Free Cash Flow
Phaarmasia operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |